AIM
ONC

Acrospire Investment Management’s BeOne Medicines Ltd ONC Stock Holding History

Acrospire Investment Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-498
Closed -$15K – 2543
2016
Q4 		$15K Buy
+498
New +$15.7K 0.01% 1862

Other funds holding ONC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acrospire Investment Management's ONC Position: Q1 2017 in Review

Acrospire Investment Management sold out of BeOne Medicines Ltd (ONC) in Q1 2017, closing a stake of 498 shares — an estimated $15K sold.

Acrospire Investment Management first reported a position in ONC in Q4 2016 and held it in 1 quarter. The position peaked at $15K in Q4 2016. 56 funds tracked by Wall St. Rank hold ONC as of Q1 2017.

  • Acrospire Investment Management reported no remaining BeOne Medicines Ltd position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 498 BeOne Medicines Ltd shares in Q1 2017, an estimated $15K.
  • Acrospire Investment Management first reported a position in BeOne Medicines Ltd in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's BeOne Medicines Ltd position peaked at $15K in Q4 2016.
  • 56 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.